DOI: https://doi.org/10.22263/2312-4156.2022.6.78
A.T. Shchastniy, A.S. Osochuk, S.S. Osochuk, A.F. Martsinkevich
The influence of end-stage kidney failure on the composition of native blood lipoprotein complexes in men and women
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2022;21(6):78-84.
Abstract.
Objectives. To determine the effect of end-stage renal failure on the biochemical composition of blood lipoprotein complexes.
Material and methods. The work is carried out within the frames of the State Research Program «Translational Medicine, 2020 - 2025», subprogram 4.2 «Fundamental Aspects of Medical Science» on task 3.37, State Registration Number 20220305. The study group of patients was composed of 15 men (36-60 years old) and 16 women (36-55 years old) with the end-stage chronic kidney disease, the control group consisted of 15 healthy men and women of the same age. Lipoprotein complexes (LPC) were isolated by sequential ultracentrifugation on the preparative ultracentrifuge, the amount of protein in native LPC was determined by the Lowry method, cholesterol and triacylglycerides – by a biochemical method, proprotein convertase subtilisin kexin 9 (PCSK9) – by enzyme immunoassay in blood serum.
Results. There are no gender differences characteristic of healthy subjects in the individuals of the study group. In patients with chronic renal failure (CRF), the level of VLDL TG is higher than that in the control group, and cholesterol and VLDL protein are increased compared to healthy women. The amount of LDL TG in the study group is higher compared to the control group, and the amount of LDL protein is increased in comparison with women in the control group.
Conclusion. CRF possesses a proatherogenic effect and eliminates gender differences characteristic of healthy individuals, and it also has a stronger effect on women, increasing the content of total VLDL cholesterol and VLDL and LDL protein. CRF does not affect the amount of PCSK9.
Keywords: CRF, lipoprotein complexes, cholesterol, protein, PCSK9.
Information about the source of support in the form of grants, equipment, medicinal agents. The research was carried out within the frames of the State Research Program (GPNI) “Translational medicine”, subprogram 4.2 “Fundamental aspects of medical science”, task 3.37 “To study the condition of lipid transport and immune systems of patients with kidney transplantation and to substantiate the approaches to their correction”, State Registration No. 20220305 dated 16.03.2022. The authors didn’t get any financial support on the part of medicines producing companies.
References
1. Marsche G, Heine GH, Stadler JT, Holzer M. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease. Biomolecules. 2020 Sep;10(9):1348. doi: http://dx.doi.org/10.3390/biom10091348
2. Kastarinen H, Hörkkö S, Kauma H, Karjalainen A, Savolainen MJ, Kesäniemi YA. Low-density lipoprotein clearance in patients with chronic renal failure. Nephrol Dial Transplant. 2009 Jul;24(7):2131-5. doi: http://dx.doi.org/10.1093/ndt/gfp026
3. Shao B, Mathew AV, Thornock C, Pennathur S. Altered HDL proteome predicts incident CVD in chronic kidney disease patients. J Lipid Res. 2021;62:100135. doi: http://dx.doi.org/10.1016/j.jlr.2021.100135
4. Varga É, Seres I, Harangi M, Kárpáti I, Koncsos P, Sztanek F, et al. Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure. Kidney Blood Press Res. 2012;35(4):265-72. doi: http://dx.doi.org/10.1159/000334650
5. Strazzella A, Ossoli A, Calabresi L. High-Density Lipoproteins and the Kidney. Cells. 2021 Mar;10(4):764. doi: http://dx.doi.org/10.3390/cells10040764
6. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992 Jun;41(6):1653-61. doi: http://dx.doi.org/10.1038/ki.1992.238
7. Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis. 2001 Jul;38(1):70-6. doi: http://dx.doi.org/10.1053/ajkd.2001.25196
8. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996 Jun;97(12):2917-23. doi: http://dx.doi.org/10.1172/JCI118751
9. Reade V, Mezdour H, Reade R, Kandoussi M, Dracon M, Fruchart JC, et al. Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients. Am J Nephrol. 1996;16(5):394-401. doi: http://dx.doi.org/10.1159/000169031
10. A Iglesias, Montelongo A, Herrera E, Lasunción MA. Changes in cholesteryl ester transfer protein activity during normal gestation and postpartum. Clin Biochem. 1994 Feb;27(1):63-8. doi: http://dx.doi.org/10.1016/0009-9120(94)90013-2
11. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000 Apr;101(16):1907-12. doi: http://dx.doi.org/10.1161/01.cir.101.16.1907
12. Sönmez D, Fidan Y, Ozcan O, Azak A, Seneş M, Duranay M, et al. Is there a relationship between small, dense LDL and lipoprotein-associated phospholipase A2 mass in dialysis patients? Clin Lab. 2014;60(9):1431-7.
13. Bairaktari E, Elisaf M, Tzallas C, Karabina SA, Tselepis AD, Siamopoulos KC, et al. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). Clin Biochem. 2001 Nov;34(8):593-602. doi: http://dx.doi.org/10.1016/s0009-9120(01)00274-0
14. Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, et al. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of NondialysisChronic Kidney Disease Patients. Oxid Med Cell Longev. 2021 Jul;2021:6677012. doi: http://dx.doi.org/10.1155/2021/6677012
15. Bajaj A, Xie D, Cedillo-Couvert E, Charleston J, Chen J, Deo R, et al. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. Am J Kidney Dis. 2019 Jun;73(6):827-836. doi: http://dx.doi.org/10.1053/j.ajkd.2018.11.010
16. Bunak VV. Allocation of stages of ontogenesis and chronological boundaries of age periods. Sovet Pedagogika. 1965;(11):105-19. (In Russ.)
17. Perkins EG, Lindgren FT. Analysis of lipids and lipoproteins. American Oil Chemists' Society, Champaign III; 1975.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265-75.
19. Bates D, Machler M, Bolker B, Walker SJ. Fitting Linear Mixed-Effects Models Usinglme 4. J Stat Software. 2015;67(1):1-48. doi: http://dx.doi.org/10.18637/jss.v067.i01
20. Searle SR, Speed FM, Milliken GA. Population Marginal Means in the Linear Model: An Alternative to Least Squares Means. Am Stat. 1980 Nov;34(4):216-21. doi.org/10.2307/2684063
21. Furusyo N, Ai M, Okazaki M, Ikezaki H, Ihara T, Hayashi T, et al. Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women. Atherosclerosis. 2013 Dec;231(2):238-45. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2013.09.008
22. Carlson LA, Ericsson M. Quantitative and qualitative serum lipoprotein analysis. Part 1. Studies in healthy men and women. Atherosclerosis. 1975 May-Jun;21(3):417-433.
23. Semmens J, Rouse I, Beilin LJ, Masarei JR. Relationship of plasma HDL-cholesterol to testosterone, estradiol, and sex-hormone-binding globulin levels in men and women. Metabolism. 1983 May;32(5):428-32. doi: http://dx.doi.org/10.1016/0026-0495(83)90002-1
24. Desai NK, Ooi EM, Mitchell PD, Furtado J, Sacks FM. Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans. Atherosclerosis. 2015 Aug;241(2):326-33. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.013
25. Palmer BF, Clegg DJ. Gonadal dysfunction in chronic kidney disease. Rev Endocr Metab Disord. 2017 Mar;18(1):117-130. doi: http://dx.doi.org/10.1007/s11154-016-9385-9
26. Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. Ann Clin Biochem. 2016 May;53(Pt 3):377-84. doi: http://dx.doi.org/10.1177/0004563215610589
Information about authors:
A.T. Shchastniy – Doctor of Medical Sciences, professor, head of the Chair of Hospital Surgery with the course of the Faculty for Advanced Training & Retraining, rector of Vitebsk State Order of Peoples’ Friendship Medical University, ORCID: https://orcid.org/0000-0003-2796-4240
A.S. Osochuk – postgraduate of the Chair of Hospital Surgery with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0002-5942-3601
E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Alexander S. Osochuk.
S.S. Osochuk – Doctor of Medical Sciences, professor, head of the research laboratory, Vitebsk State Order of Peoples’ Friendship Medical University, ORCID: https://orcid.org/0000-0003-2074-3832
A.F. Martsinkevich – Candidate of Biological Sciences, associate professor of the Chair of General & Clinical Biochemistry with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0003-3655-4489
